Publications by authors named "Brandon Locke"

Alzheimer's disease (AD) is an incurable and progressive neurodegenerative disease with increasing prevalence worldwide. Previous trials of anti-amyloid and anti-tau immunotherapy indicate that additional research needs to be conducted on other mechanisms to find curative or disease-modifying therapy. This review focuses on apolipoprotein E (ApoE), a critical protein in brain lipid metabolism that acts specifically in the clearance and transport of lipids and cholesterol.

View Article and Find Full Text PDF

Background: In patients with inflammatory bowel disease (IBD), multimorbidity with obesity and type 2 diabetes is common and increasing. Glucagon-like peptide 1 (GLP-1) receptor agonists are increasingly being prescribed for patients with IBD, yet their impact on patients with IBD is largely unknown. We aimed to assess the impact of GLP-1 receptor agonists on the course of IBD.

View Article and Find Full Text PDF

The surface of the eye is directly exposed to the external environment, protected only by a thin tear film, and may therefore be damaged by contact with ambient particulate matter, liquids, aerosols, or vapors. In the workplace or home, the eye is subject to accidental or incidental exposure to cleaning products and pesticides. Organic matter may enter the eye and cause infection.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Brandon Locke"

  • - Brandon Locke's research encompasses a range of medical topics, including neurodegenerative diseases, inflammatory bowel disease, and ocular surface injuries, reflecting a multidisciplinary approach to health challenges.
  • - In his recent article on Alzheimer's disease, Locke emphasizes the role of apolipoprotein E (ApoE) in the disease's pathogenesis and the need to explore additional therapeutic mechanisms beyond current treatment strategies.
  • - Another significant study evaluates the safety of GLP-1 receptor agonists in patients with inflammatory bowel disease, finding no increase in exacerbation rates, which supports their use among this patient population.